

# Monash Investors Small Companies Trust

## Hedge Fund (ASX : MAAT)



High Conviction Fund



Australian Small Companies



Proven Track Record<sup>1</sup>



Buy and Sell on the ASX or direct


### December 2023 Fund Update

The market continued to rise in December with the Fund up 5.1% after fees compared to the S&P/ASX Small Ords up 7.2% for the month. The Small Ords finished up 7.8% for the year, so the entire year's gains pretty much all came down to this last month.

Our Fund's performance in the last quarter lagged the market, we were up 2.5% compared to 8.5% for the Small Ords. This offset the outperformance that we had achieved over the prior 9 months. For the full year we finished up 2.4% compared to the Small Ords' 7.8%. Whilst disappointing, we have seen this pattern numerous times before, with the portfolio subsequently rewarding us for patience and conviction

So, what caused the market to turn around in the last quarter? The likeliest explanation was that the market responded to recent data that inflation continues to normalise. We have seen the peak in interest rates, so central banks will eventually follow with rate cuts. Figure 1 shows global inflation and it is quite a striking chart. We are now re-entering the inflation range that existed for most of the 2010's.

### Global headline inflation – monthly annualised run-rate



Source: UBS, Haver

<sup>1</sup> Inception date is 28 May 2021. Past performance is not indicative of future performance.

### Return Summary<sup>1</sup> (after all fees)

1 Month	3 Months
+5.1%	+2.5%
1 Year	Since Inception
+2.4%	-0.8% <sub>pa</sub>



Our Investment team: Sebastian Correia, Simon Shields and Shane Fitzgerald

This fund is appropriate for investors with "High" and "Very High" risk and return profiles. A suitable investor for this fund is prepared to accept high risk in the pursuit of capital growth with a medium to long investment timeframe. Investors should refer to the [TMD](#) for further information.



# Monash Investors Small Companies Trust

## Hedge Fund (ASX : MAAT)

### Portfolio Commentary

So why did the Fund lag the market this quarter? The short answer is that our portfolio is concentrated and our largest positions didn't pull their weight. Over time our Fund has been well served by its concentration and we are confident that despite this volatility it will do so in the future.

Our largest 15 stocks represent about 73% of the portfolio. Six of these stocks went up, on average by about 20% for the quarter, which was well ahead of the market's return of 8.5%. One was flat but the other eight went down, by an average of about -11%.

None of the stocks that fell have anything significantly wrong with their businesses. All are either leaders in their industries or otherwise well placed to take advantage of growth opportunities. Collectively, we are expecting an

average upside pay-off to our calculated valuations of more than 60% from these stocks. We consider each below.

### The Uranium stocks

The price of Uranium has risen steadily over the year, reaching a high of around \$90/lb recently, up from around \$50/lb at the start of the year. Our exposures to the sector are Boss Energy and Paladin (ASX: BOE & PDN), both of which have large reserves in good jurisdictions, strong management expertise and are low risk plays on the commodity. We have discussed the prospects for uranium supply and demand in a previous monthly fund update, and it remains highly favourable. Despite their stock prices going backwards this quarter, we are still up about 30% on our average entry prices, with significant upside remaining.

Return Summary Since Inception (after fees) <sup>2</sup>		
	MAAT	Small Ords
CYTD	2.44%	7.82%
FYTD	0.79%	6.42%
1 month	5.09%	7.23%
3 Month	2.54%	8.52%
6 Month	0.79%	6.42%
1 Year	2.44%	7.82%
2 Years pa	-7.28%	-6.19%
Since Inception pa	-0.76%	-1.70%

Return Summary Since Inception (after fees) <sup>2</sup>		
	MAIF	Small Ords
CYTD	2.95%	7.82%
FYTD	0.94%	6.42%
1 month	4.73%	7.23%
3 Month	1.99%	8.52%
6 Month	0.94%	6.42%
1 Year	2.95%	7.82%
2 Years pa	-6.78%	-6.19%
3 Years pa	0.59%	0.95%
4 Years pa	7.47%	2.95%
5 Years pa	12.82%	6.40%
7 Years pa	7.80%	5.91%
Since Inception pa	9.34%	5.92%

<sup>2</sup>Due to lack of MAAT history, data from Monash Small Companies Fund (MAIF) (inception date 2 July 2012) has been used. Glossary of terms can be found on the Fund's website at [www.monashinvestors.com/glossary/](http://www.monashinvestors.com/glossary/)

# Monash Investors Small Companies Trust

## Hedge Fund (ASX : MAAT)

### Healthcare

Our two healthcare stocks are Impedimed and Telix (ASX: IPD & TLX). Again, we have reviewed these stocks in previous updates. Telix continues to strongly grow its radiopharmaceutical sales and has a pipeline of new drugs to come. Impedimed is becoming the standard of care to monitor cancer patients for lymphedema, and has recently had a board and management shakeout that should lead to an even more highly focused business.

### Johns Lyng and NextEd

It's been a while since we reviewed Johns Lyng (ASX: JLG) in an update. It continues to grow its building services business strongly in Australia and the USA as a preferred supplier to insurance companies and strata bodies in Australia and Home Owners Associations in the USA. JLG is in a strong position to capture revenue from both regular repair work and catastrophic restoration projects in Australia and the USA.

NextEd (ASX: NXD) was the closest we had to a problem stock for the quarter. It was down 21% on the back of the Federal government targeting student visa loopholes to reduce immigration, despite an ongoing recovery in its business post Covid. Ironically NextEd is likely to be a winner from the federal government changes because it is a highly reputable provider, that is well-placed to capture students seeking to remain in Australia under the revised student visa programmes.

### Two larger cap stocks

While we are focused on small companies, we do also hold a limited number of larger cap stocks in the Fund. Among them are QBE, the insurance company, and Technology One, the accounting and organizational software provider (ASX: QBE & TNE).

QBE is a beneficiary of rising insurance premiums and TNE also continues to raise its margins through pricing

**Our largest 15 stocks represent about 73% of the portfolio. Six of these stocks went up, on average by about 20% for the quarter, which was well ahead of the market's return of 8.5%. One was flat but the other eight went down, by an average of about -11%.**

power. The businesses of both continue to do well and they are both trading at the lower end of their valuation multiple range. These stocks are well placed for both earnings growth and multiple re-rating.

### Looking at the portfolio as a whole

Monash Investors aims to identify businesses which are likely to undergo step-changes in their business prospects which will lead to material share price movements. We draw upon our experience in order to exploit recurring business situations and patterns of behaviour, to identify and invest in a portfolio of compelling opportunities.

Our retail exposures Temple & Webster and Lovisa (ASX: TPW & LOV) did very well over the quarter as did our gold stocks and mining services exposures.

The Fund's major exposures continue to be to Healthcare, Consumer Discretionary, IT, Energy (via Uranium), and Mining Services.

<sup>2</sup>Due to lack of MAAT history, data from Monash Small Companies Fund (MAIF) (inception date 2 July 2012) has been used. Glossary of terms can be found on the Fund's website at [www.monashinvestors.com/glossary/](http://www.monashinvestors.com/glossary/)

# Monash Investors Small Companies Trust

## Hedge Fund (ASX : MAAT)

### **For MAAT Unit Registry enquiries, please contact**

Apex Fund Services Pty Limited  
P: 1300 133 451 (in Australia)  
+61 2 8259 8888 (international)  
E: [registry@apexgroup.com](mailto:registry@apexgroup.com)

### **For all business development enquiries, please contact**

Cameron Harris  
P: +61 400 248 435  
[cameron@gsmcapital.com.au](mailto:cameron@gsmcapital.com.au)

**For more information about MAAT and the strategy, please refer to the Monash Investors website at [www.monashinvestors.com](http://www.monashinvestors.com). You can also [follow us on Livewire here](#) or [subscribe to our updates here](#)**

This document is prepared by Monash Investors Pty Limited ABN 67 153 180 333, AFSL 417 201 ("Monash Investors") as authorised representatives of Sanlam Private Wealth Pty Ltd ABN 18 136 960 775, AFSL 337 927 ("Sanlam") for the provision of general financial product advice in relation to the Monash Investors Small Companies Trust (Hedge Fund) ARSN 642 280 331 ("Fund") and authorised for release by The Trust Company (RE Services) Limited ABN 45 003 278 831, AFSL 235 150 ("Perpetual") as the responsible entity of, and issuer of units in the Fund. Monash Investors is the investment manager of the Fund. A Product Disclosure Statement ("PDS") dated 17 July 2023 together with a Target Market Determination ("TMD"), both issued by Perpetual, is available for the Fund at [www.monashinvestors.com](http://www.monashinvestors.com). You should obtain and consider the PDS and TMD for the Fund before deciding whether to acquire, or continue to hold, an interest in the Fund. The information provided is general information only and is not intended to provide you with financial advice, it does not consider your investment objectives, financial situation or particular needs. You should consider your own investment objectives, financial situation and particular needs before acting upon any information provided and consider seeking advice from a financial advisor if necessary. To the extent permitted by law, no liability is accepted for any loss or damage as a result of any reliance on this information. No company in Perpetual Group (Perpetual Limited ABN 86 000 431 827 and its subsidiaries) guarantees the performance of any fund or the return of an investor's capital.

You should not base an investment decision simply on past performance. Past performance is not a reliable indicator of future performance. Returns are not guaranteed and so the value of an investment may rise or fall. Total returns shown have been calculated using NAV prices after taking into account all ongoing fees and assuming reinvestment of distribution. No allowance has been made for taxation. Comparisons are provided for information purposes only and are not a direct comparison against benchmarks or indices that have the same characteristics as the Fund. Reference to Target Distributions, is a target return only. There is no guarantee the Fund will meet its investment objective. The payment of a quarterly distribution is a goal of the Fund only and neither Monash Investors or Perpetual provide any representations or warranty (whether express or implied) in relation to the payment of any quarterly cash income. The Fund reserves the discretion to amend its distribution policy.

The rating contained in this document is issued by SQM Research Pty Ltd ABN 93 122 592 036 AFSL 421913. SQM Research is an investment research firm that undertakes research on investment products exclusively for its wholesale clients, utilising a proprietary review and star rating system. The SQM Research star rating system is of a general nature and does not take into account the particular circumstances or needs of any specific person. The rating may be subject to change at any time. Only licensed financial advisers may use the SQM Research star rating system in determining whether an investment is appropriate to a person's particular circumstances or needs. You should read the product disclosure statement and consult a licensed financial adviser before making an investment decision in relation to this investment product. SQM Research receives a fee from the Fund Manager for the research and rating of the managed investment scheme.